Overview

• Omeros Q3 net loss narrows to $30.9 mln from $32.2 mln in prior year

• Company entered into a $2.1 bln asset purchase agreement with Novo Nordisk

• Omeros prepares for potential FDA approval of narsoplimab in TA-TMA

Outlook

• Omeros expects to receive $240 mln upfront from Novo Nordisk deal in Q4 2025

• Company anticipates FDA decision on narsoplimab by December 26, 2025

Result Drivers

• EXPENSE REDUCTION - Omeros reduced expenditures on various programs to conserve capital for the expected commercial launch of narsoplimab in TA-TMA

• NOVO NORDISK AGREEMENT - Omeros entered an agreement with Novo Nordisk for up to $2.1 bln in payments, including $240 mln upfront, for rights to zaltenibart

• NARSOPLIMAB PREPARATIONS - Omeros is preparing for the potential FDA approval of narsoplimab, including assembling a commercial team and engaging with stakeholders

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Omeros Corp is $36.00, about 80.9% above its November 12 closing price of $6.89

Press Release: ID:nBw8HJb63a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)